Advanced Oncotherapy (AVO) – Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it was informed yesterday that Dr Enrico Vanni, a Non-Executive Director of the Company, yesterday purchased 75,000 ordinary shares of 25 pence each in the Company (“Ordinary Shares”) at an average price of 64.7 pence per Ordinary Share. Following […]

Advanced Oncotherapy (AVO) – Exercise of Options and Issue of Shares

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that is has today issued 36,946 new ordinary shares of 25 pence in the Company to Dr Enrico Vanni, a non-executive director, at a subscription price of 101.5 pence per Ordinary Share (being the closing mid price on 04 November 2016) in […]

Advanced Oncotherapy – Director Dealing and Award of Options

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Enrico Vanni, a Non-Executive Director of the Company, had on 14th July purchased 1,000,000 ordinary shares of 1 penny each in the Company at 7.9 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 14,050,000 Ordinary Shares representing 1.02% of […]

Advanced Oncotherapy – Exercise of Warrants and Issue of Shares

Exercise of Warrants and Issue of Shares. Issue of Shares Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has today issued 600,000 new ordinary shares of 1p in the Company at a subscription price of 8 pence per Ordinary Share to Dr Enrico Vanni, a non-executive director, […]